Alzheimer's research is moving beyond amyloid, with a wider breadth of targets and ability to stand up clinical trials that track and determine the relationship between biomarkers and clinical outcomes.
It's time to Focus on Broader Alzheimer's Drug Pipeline
Comment
Show comments
Hide Comments
